RxDoctor Payments DataLook up a doctor →

Rajesh Mallela, MD

Interventional Cardiology · Kokomo, INNPI 1487622304

Payments from drug & device makers

$34,159in general payments, 2019–2025

Across 674 payments — averaging $50.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$10K
  • Medtronic$3K
  • Penumbra, Inc.$3K
  • Inari Medical, Inc.$3K
  • Abbott$2K
  • Cardiovascular Systems Inc.$1K
  • plus $13K from 51 others

What the payments were for

  • Travel & lodging$7,20121%
  • Food & beverage$26,85879%
  • Education$990%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,159 in reported general payments places this provider in the 80th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$358,560
Medicare patients
1,544
Services billed
5,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban408$484,345
EntrestoSacubitril/Valsartan190$286,341
XareltoRivaroxaban151$197,091
Repatha SureclickEvolocumab156$187,335
VascepaIcosapent Ethyl82$49,999
Praluent PenAlirocumab30$41,319
JardianceEmpagliflozin31$37,601
BrilintaTicagrelor18$22,681
Ranolazine ErRanolazine176$19,747
NexlizetBempedoic Acid/Ezetimibe21$17,181
Icosapent Ethyl38$13,621
Atorvastatin Calcium925$10,861
Rosuvastatin Calcium739$10,636
Carvedilol625$6,665
Potassium Chloride257$6,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$240$484,345408 claims
NovartisEntresto$1,205$286,341190 claims
Johnson & JohnsonXarelto$921$197,091151 claims
Boehringer IngelheimJardiance$245$37,60131 claims
AstraZenecaBrilinta$1,105$22,68118 claims
Esperion Therapeutics, Inc.Nexlizet$30$17,18121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →